inmunebio.com Revenue and Competitors
Estimated Revenue & Valuation
- inmunebio.com's estimated annual revenue is currently $4.3M per year.
- inmunebio.com's estimated revenue per employee is $155,000
Employee Data
- inmunebio.com has 28 Employees.
- inmunebio.com grew their employee count by 17% last year.
inmunebio.com's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and CMO | Reveal Email/Phone |
2 | VP CNS Development | Reveal Email/Phone |
3 | Head Medical Affairs | Reveal Email/Phone |
4 | VP Regulatory Affairs | Reveal Email/Phone |
5 | VP Clinical Operations | Reveal Email/Phone |
6 | Chief Financial Officer | Reveal Email/Phone |
7 | Associate Director Clinical Operations | Reveal Email/Phone |
8 | Clinical Research Associate | Reveal Email/Phone |
9 | Assoc. General Counsel | Reveal Email/Phone |
10 | Senior Scientist | Reveal Email/Phone |
inmunebio.com Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is inmunebio.com?
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient's immune system to treat cancer. INKmune, the company's lead product, primes patient's NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease. Media coverage provided for informational purposes only and third party links provided as a resource. INmune Bio does not control the content of third parties. XPro1595, Quellor, LIVNate, INB03, INKmune and other drug candidates, have not yet been shown to be safe or effective, and has not been approved by any regulatory body.
keywords:N/A
N/A
Total Funding
28
Number of Employees
$4.3M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
inmunebio.com News
INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform...
Boca Raton, FL, April 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing...
INmune Bio Plans to Enroll 201 Patients in a 6-Month Study to Evaluate Cognitive Function in Patients with Mild Alzheimer's Disease. April 13,...
Other Companies in La Jolla
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 28 | 47% | N/A |
#2 | $2M | 29 | 38% | $6.7M |
#3 | $3.5M | 30 | 25% | N/A |
#4 | $3.5M | 30 | 7% | N/A |
#5 | $4.9M | 30 | -19% | N/A |